TABLE 2

Clinical and pathological baseline characteristics of patients eligible for post-nivolumab treatment

Did not receive further chemotherapyReceived further chemotherapyp-value
Patients76 (40)115 (60)
Age at nivolumab initiation65.5 (34–86)63 (17–84)0.11
Sex0.78
 Male52 (68)76 (66)
 Female24 (32)39 (34)
Smoking history0.69
 Never-smoker6 (8)10 (9)
 Current or ex-smoker68 (89)104 (90)
 Missing data 2 (3)1 (1)
Histology on initial biopsy0.91
 Adenocarcinoma46 (61)72 (63)
 Squamous cell carcinoma22 (29)30 (26)
 Other8 (11)13 (11)
Stage at diagnosis0.57
 I–II7 (9)8 (7)
 III–IV69 (91)107 (93)
Lines of therapy before nivolumab0.68
 01 (1)0 (0)
 130 (39)43 (37)
 223 (30)34 (30)
 ≥322 (29)38 (33)
Performance status at nivolumab initiation0.028
 010 (13)28 (24)
 135 (46)61 (53)
 221 (28)15 (13)
 31 (1)0 (0)
 40 (0)0 (0)
 Missing9 (12)11 (10)
Metastatic sites at nivolumab initiation0.49
 Lung31 (41)48 (42)
 Pleura27 (36)36 (31)
 CNS13 (17)20 (17)
 Liver17 (22)13 (11)
 Adrenal glands19 (25)15 (13)
 Bone21 (28)26 (23)
Number of nivolumab injections before progression580.001
Performance status at first tumour evaluation<0.0001
 00 (0)23 (20)
 120 (26)41 (36)
 219 (25)21 (18)
 316 (21)7 (6)
 47 (9)0 (0)
 Missing14 (18)23 (20)

Data are presented as n (%), median (range) or median, unless otherwise stated. n=191. CNS: central nervous system. Bold type represents statistical significance.